If an agent that is able to sensitize breast cancer to PI3K inhibitors is identified and applied, lower doses of these inhibitors could then be used to achieve an increased therapeutic index in patients, which will also translate to a reduced side effect profile in patients. The gene discussed is PIK3CA; the disease is breast cancer.